Peginesatide
As of the edition of 20 October 2026, Peginesatide is a protein: withdrawn from the market in 2019; acts on EPOR; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Withdrawn from market, 2019
- Kind
- Protein
- Brand name
- Omontys Preservative Free
- First approved
- 27 March 2012 (US)
- Approvals on record
- 8 in 1 region
- Holder of the most recent approval
- Takeda
- Withdrawn from market
- 1 January 2019 (in some regions)
- Registered trials
- 19, 5 stopped early
- Disease areas
- Blood and lymph; Pregnancy and women's health; Urinary and reproductive; Cancer
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Peginesatide.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| EPOR | Erythropoietin receptor | P19235 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 1 | 0 | 1 |
| Phase 2 | 11 | 8 | 0 | 3 |
| Phase 3 | 5 | 5 | 0 | 0 |
| Phase 4 | 1 | 0 | 0 | 1 |
| All trials | 19 |